BSX Boston Scientific
- Official Name: BOSTON SCIENTIFIC CORPORATION
- Headquarters: 300 Boston Scientific Way, MARLBOROUGH, MA, 01752-1234 US
- CEO: Michael F. Mahoney
- Website: bostonscientific.com
- Key Investor: BLACKROCK, INC | 9.58%
- Dedicated Investor: BOLLARD GROUP LLC | 54.28%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-16 | 1 | Won by 0.219 | 0.169 - (0.050) | ||
| 2025-07-23 | 2 | Lost by 0.660 | 3.983 - 4.643 | ||
| 2025-07-29 | 2R | Lost by 0.105 | 1.003 - 1.108 | ||
| 2025-07-30 | 3 | Lost by 1.300 | (0.105) - 1.195 | ||
| 2025-08-06 | 4 | Lost by 5.150 | (4.032) - 1.118 | ||
| 2025-08-07 | 1R | Won by 0.265 | 0.078 - (0.187) | ||
| 2025-08-13 | 5 | Lost by 0.628 | (0.513) - 0.115 | ||
| 2025-08-20 | 6 | Won by 1.320 | 3.214 - 1.894 | ||
| 2025-08-21 | 2R | Lost by 2.287 | (1.006) - 1.281 | ||
| 2025-08-27 | 7 | Lost by 2.799 | (0.168) - 2.631 | ||
| 2025-09-03 | 8 | Won by 1.575 TOTW | 1.713 - 0.138 | ||
| 2025-09-10 | 9 | Lost by 2.594 | (2.114) - 0.480 | ||
| 2025-09-17 | 10 | Lost by 5.920 | (5.060) - 0.860 | ||
| 2025-09-17 | 1R | Lost by 2.180 | (0.437) - 1.743 | ||
| 2025-09-24 | 11 | Won by 1.291 | (0.387) - (1.678) | ||
| 2025-10-01 | 12 | Won by 3.447 | (1.976) - (5.423) | ||
| 2025-10-08 | 13 | Won by 4.077 | 0.862 - (3.215) | ||
| 2025-10-15 | 14 | Won by 2.050 | 0.924 - (1.126) | ||
| 2025-10-22 | 15 | Won by 6.882 | 6.754 - (0.128) |
Latest News

How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Busines...

Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevat...

Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.

Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk
Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.

Boston Scientific begins to restore shipping after cyberattack
The company is working through a backlog after the cyberattack hampered manufacturing, order processing and shipping.

Did Recalls And Cyberattack Disruptions Just Shift Boston Scientific's (BSX) Investment Narrative?
In recent weeks, Boston Scientific has faced multiple voluntary global recalls of its Suture Cinch endoscopic devices and ENROUTE Transcarotid Neuropr...

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.

Protolabs CEO sees big impact from US reshoring despite potential tariffs
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additiona...

Boston Scientific (BSX) Could Be 23% Undervalued After Recalls And Cyber Incident
Boston Scientific (BSX) is back in focus after a series of voluntary global recalls affecting its ENROUTE Transcarotid Neuroprotection Systems and Ove...

Thursday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.

Boston Scientific (BSX) Issues Multiple Worldwide Product Recalls
Boston Scientific (NYSE: BSX) has initiated multiple worldwide product recalls, including a Class I recall of its ENROUTE Transcarotid Neuroprotection...
FDA Says Aware Boston Scientific Issued Letter To Affected Customers Recommending Unused Infinion CX Leads Be Removed From Where They Are Used/Sold; As Of May 27, 2026, Boston Scientific Reported 1,081 Serious Injuries And No Deaths Associated With Issue Related To Infinion CX Leads
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/spinal-cord-stimulator-recall-boston-scientific-removes-infinion-cx-lead

Boston Scientific (BSX) Stock Looks Cheap After a 55% Slump
Boston Scientific stock has had a steep year, with a sharp share price decline set against valuation checks that point to a potentially cheap entry po...

Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exi...

1 Stock Under $50 to Target This Week and 2 We Ignore
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less r...

The Wide Divide Priced Into Boston Scientific Stock
The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underly...

2 Reasons to Watch BSX and 1 to Stay Cautious
Boston Scientific has gotten torched over the last six months - since March 2026, its stock price has dropped 36.9% to $48.10 per share. This was part...

How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?
Despite Boston Scientific’s weak performance relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock...

The Peer-Group Mispricing Sitting On BSX Stock
This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top...

Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.